Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

Schreiner MediPharm’s new Digital Display Label allows trial sponsors to eliminate time-consuming manual relabeling.

Provides ReciBioPharm’s customers with access to NewBiologix’s Xcell-Eng-HEK293 celllines to develop and manufacture AAV ...

Gilead Sciences is investing an additional $11 billion into its U.S. operations, the company announced this week, bringing ...

ACG Packaging Materials’ greenhouse gas emission reduction targets have been validated by the Science Based Targets ...